Fairmount Funds Management LLC

-

Assets, Funds, Holdings

Home | Sign Up | Log In
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Fairmount Funds Management LLC
CRD #284844
SEC #801-116848
CIK #0001802528
AUM 5,799.1 M (2026-03-31)
Employees 30 (40% Investors, 0% Brokers)
Fees
Minimum
Phone267-262-5300
Address200 Barr Harbor Drive
West Conshohocken, PA 19428
Source [IAPD] [EDGAR] [Website] [LinkedIn]
Total AUM ($B)
6.04.83.62.41.20.02010201520212027
Fees and Compensation — Form ADV Part 2A (3/31/2026) [Brochure]
Item 5: Fees and Compensation
Management Fee

With respect to the Partnerships, Fairmount receives a management fee of 1.25% per annum
based on the net asset value attributable to each Investor’s capital account. Management fees
are paid quarterly in advance and are directly deducted from Investor accounts. The
management fees are calculated independently by the Partnerships’ administrator and
reviewed by Fairmount’s Chief Financial Officer. Fairmount may, in its discretion, waive,
reduce, or rebate management fees with respect to certain Investors, including affiliates of
the General Partners or Fairmount. No such waiver, reduction, or rebate will entitle any other
Investor to similar treatment.

Fairmount does not receive a management fee in connection with its management of Co-
Invest III, Co-Invest IV, or Co-Invest V.

Additional Fees and Expenses

The Funds pay certain specific and customary expenses, including those detailed in their
respective governing documents and agreements. These expenses typically include: (i) fees,
costs, and expenses relating to attorneys, accountants, advisers, consultants (including
sourcing, operating, research, industry expert, and other subject-matter consultants, as well
as scientists and engineers), administrators, custodians, depositaries and paying agents,
domiciliation agents, valuation experts, and data providers (including related systems,
services, data management software, and information technology incorporated into the cost
of obtaining such data); fees for temporary or long-term personnel or consultants engaged by
Fairmount, including strategic advisors, senior advisors, and similar professionals who are not
Fairmount employees but may be employees of portfolio companies or other entities in which
a Fund invests); and fees relating to audit and certification, preparation and distribution of
Investor reports, maintaining accounts, calculating net asset values, processing subscriptions,
and Investor communications; (ii) fees payable to any placement agent engaged pursuant to
local legal or regulatory requirements in connection with the offering of Fund interests outside
the United States; (iii) brokerage commissions, prime brokerage fees, custodial expenses,
other bank service fees and other investment costs, fees and expenses; (iv) expenses
associated with auditing; (v) trade support services, including, pre- and post-trade support
software and related services (including any and all fees, costs and expenses of any
investment, books and records, portfolio compliance and reporting systems such as
Bloomberg terminals, including consultant, software licensing, data management and
recovery services fees and expenses) and data services providing price feeds, news feeds,
security and company information and company fundamental data; (vi) risk analysis, risk
reporting, and risk-related and consulting services provided by third parties; (vii) fees of
providers of specialized data or analysis related to portfolio companies and the sector and
asset classes in which a Fund has made or intends to make investments; (viii) research and
technology expenses (including newswire, quotation services, publications, periodicals,
subscriptions, database services, data processing related to research activities, and other
information services); (ix) expenses associated with Investor communications and reporting
(including annual information sessions or meetings and the maintenance of a website or other
investor portal); (x) investment-related travel expenses (including transportation, lodging,
internet access fees, international cellular charges, out-of-office meals, and other similar
expenses); (xi) fees, costs, and expenses incurred in developing, bidding on, evaluating,
investigating, negotiating, financing, refinancing, structuring, obtaining regulatory approvals
for, purchasing, trading, clearing, settling, monitoring, maintaining custody of, holding and

Fairmount Funds Management LLC                                                 Form ADV Part 2A

disposing of investments, whether or not consummated, including due diligence, valuation,
financing, legal, accounting, advisory, and consulting expenses, costs related to proxy contests
(including professional fees); foreign exchange and other currency transaction costs;
insurance, indemnity, litigation, investigation, and similar expenses; and any expenses related
to short sales; (xii) expenses associated with withdrawals, redemptions, distributions,
admissions, issuances and transfers of Fund interests (including preparation of any form
transfer agreements); provided that the applicable transferor/transferee shall bear the
material costs of any such transfer; (xiii) expenses associated with the acquisition, holding,
monitoring, and disposition of investments, including brokerage, trading, custody, and
hedging costs, commissions, and similar expenses incurred in connection with receiving,
buying, selling, exchanging, trading, and otherwise dealing in securities and other Fund
property (including expenses relating to spreads, short dividends, negative rebates, financing
charges, currency hedging costs, and temporary investments); (xiv) interest and other
expenses incurred in respect of a Fund’s borrowings, guarantees and other financing
arrangements; (xv) costs and expenses of any lenders, investment banks and other financing
sources; (xvi) fees, costs and expenses associated with a Fund’s financial statements, reports,
notices, tax returns and Schedule K-1s (or similar schedules), including any related audits and
the costs of preparing, translating, and distributing such materials (whether by a Fund, any
affiliate or any service provider or agent engaged in connection therewith); (xvii) out-of-pocket
fees, costs, and expenses incurred in connection with a Fund’s legal, tax, and regulatory
compliance with applicable U.S. federal, state, local, non-U.S., or other laws or regulations,
...
Account Minimums and Types of Clients — Form ADV Part 2A (3/31/2026) [Brochure]
Item 7: Types of Clients
As previously described in Item 4, Fairmount’s clients are the Funds. With respect to the Funds,
any initial and additional subscription minimums are described in the relevant offering
documents and may be waived or modified by Fairmount or its affiliates. The Funds are open
only to certain financially sophisticated investors who meet eligibility criteria.

Fairmount Funds Management LLC                                                Form ADV Part 2A
Sector Form 13F Holdings Value ($M)
Galecto Inc 225.7
Magenta Therapeutics Inc 212.9
UNUM Therapeutics Inc 211.8
Aeglea Biotherapeutics Inc 202.7
ARCA Biopharma Inc 181.7
Signal Genetics Inc 76.6
Imara Inc 72.7
Aerovate Therapeutics Inc 64.0
Glycomimetics Inc 50.5
Zenas Biopharma Inc 46.1
View All
Holdings by Sector ($M)
1400112084056028002019202120242027
Type Form D Funds Date Sold AUM
PE Fairmount Healthcare Co-Invest V LP [2026-02-10] 80.3 M
Filed 2025-11-05 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
PE Fairmount Healthcare Co-Invest IV LP [2025-02-20] 41.6 M
Filed 2024-10-31 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
PE Fairmount Healthcare Co-Invest III LP [2024-08-15] 78.6 M
Filed 2024-03-29 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Remaining Indefinite · Duration One year or less · Net Assets Decline to Disclose
PE Fairmount Healthcare Co-Invest II LP [2023-11-15] 15.2 M 24.9 M
Offered $15,173,000 · Filed 2023-08-21 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose
PE Fairmount Healthcare Co-Invest LP [2023-08-18] 25.0 M 38.7 M
Offered $25,000,000 · Filed 2023-06-30 (D) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1 · Duration One year or less · Net Assets Decline to Disclose
PE Fairmount SPV I LLC 2022-03-31 1.6 M
PE Fairmount SPV III LLC 2020-04-17 0.6 M
HF Fairmount Healthcare Fund II LP [2019-05-24] 28.0 M 5,598.6 M
Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
PE Fairmount SPV II LLC 2019-05-24 0.4 M
HF Fairmount Healthcare Fund LP [2018-02-13] 3.6 M 111.0 M
Filed 2020-10-27 (D/A) · Exemption 506(b), 3(c), 3(c)(7) · Minimum $1,000,000 · Remaining Indefinite · Duration More than one year · Net Assets Decline to Disclose
View All
AUM Breakdown Accounts AUM ($B)
By Client Type
(a) Individuals (other than high net worth individuals) 0 0.0
(b) Individuals (high net worth individuals) 0 0.0
(c) Banking or thrift institutions 0 0.0
(d) Investment companies 0 0.0
(e) Business development companies 0 0.0
(f) Pooled investment vehicles 4 5.8
(g) Pension and profit sharing plans 0 0.0
(h) Charitable organizations 0 0.0
(i) State or municipal government entities 0 0.0
(j) Other investment advisers 0 0.0
(k) Insurance companies 0 0.0
(l) Sovereign wealth funds and foreign official institutions 0 0.0
(m) Corporations or other businesses not listed above 0 0.0
(n) Other 0 0.0
Total 4 5.8
By Discretionary
Discretionary 4 5.8
Non-Discretionary 0 0.0
Total 4 5.8
By Non-United States Persons
Non-United States Persons 2.8
United States Persons 3.0
Total 4 5.8
Form D Directors Role # Filings # Firms 2011 - 2026
Tomas Kiselak Executive Officer 25 2
Peter Harwin Executive Officer 22 2
Fairmount Funds Management LLC Executive Officer 8 2
Investment Manager Fairmount Funds Management LLC Promoter 2 1
General Partner Fairmount Healthcare Fund GP LLC Executive Officer 1 1
EDGAR Form CIK 2011 - 2026
13F-HR [0001802528]
3 [0001802528]
4 [0001802528]
SC 13D [0001802528]
SC 13G [0001802528]
Form 13D/13G Filer Form 13D/13G Subject Filed
Fairmount Funds Management LLC Galecto Inc [2025-11-17]
Fairmount Funds Management LLC Glycomimetics Inc [2025-06-23]
Fairmount Funds Management LLC Jade Biosciences Inc [2025-05-01]
Fairmount Funds Management LLC Anaptysbio Inc [2024-12-18]
Fairmount Funds Management LLC Inhibikase Therapeutics Inc [2024-10-17]
Fairmount Funds Management LLC Oruka Therapeutics Inc [2024-09-06]
Fairmount Funds Management LLC Soleno Therapeutics Inc [2023-10-10]
Fairmount Funds Management LLC Dianthus Therapeutics Inc /DE/ [2023-09-21]
Fairmount Funds Management LLC Kiniksa Pharmaceuticals Ltd [2023-08-10]
Fairmount Funds Management LLC Apogee Therapeutics Inc [2023-07-21]
View All
Firm Profile (Form ADV)
ServesInstitutional
Fund TypesHedge Fund, Private Equity
LEI549300KMPFHUFJ6T6Y84
Form 3/4/5 Subject 2011 - 2026
Kiselak Tomas
Fairmount Funds Management LLC
Oruka Therapeutics Inc
Fairmount Healthcare Co-Invest III LP
Fairmount Healthcare Fund II LP
Harwin Peter Evan
Spyre Therapeutics Inc
Jade Biosciences Inc
Fairmount Healthcare Co-Invest IV LP
Apogee Therapeutics Inc
View All
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Cogent Biosciences Inc COGT
Common Stock
2026-03-31 Conversion 7,000,000
Cogent Biosciences Inc COGT
Common Stock
2026-03-31 Sell 7,000,000 $34.66 242,620,000
Cogent Biosciences Inc COGT
Series A Convertible Preferred Stock · derivative
2026-03-31 Conversion 28,000 $0.00
Damora Therapeutics Inc DMRA
Stock Option (right to buy) · derivative
2026-03-23 Grant 37,313 $0.00
Damora Therapeutics Inc GLTO
Common Stock
2026-02-09 Option exercise 5,809,000 $0.00
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
2026-02-09 Option exercise 5,809 $0.00
Damora Therapeutics Inc GLTO
Series C Preferred Stock · derivative
2026-02-09 Option exercise 2,904 $0.00
Damora Therapeutics Inc GLTO
Common Stock
2026-02-09 Option exercise 2,904,000 $0.00
Apogee Therapeutics Inc APGE
Common Stock
2026-01-22 Sell 1,750,000 $76.30 133,525,000
Cogent Biosciences Inc COGT
Common Stock
2026-01-22 Sell 3,500,000 $36.40 127,400,000
Crescent Biopharma Inc CBIO
Ordinary Shares
2025-12-04 Buy 1,360,000 $13.41 18,237,600
Crescent Biopharma Inc CBIO
Pre-Funded Warrant (Right to Buy) · derivative
2025-12-04 Buy 131,434 $13.41 1,762,530
Miragen Therapeutics Inc VRDN
Common Stock
2025-10-23 Buy 454,545 $22.00 9,999,990
Zenas BioPharma Inc ZBIO
Common Stock
2025-10-07 Buy 316,219 $19.00 6,008,161
Jade Biosciences Inc JBIO
Pre-Funded Warrant (Right to Buy) · derivative
2025-10-06 Grant 855,047 $9.14 7,815,130
Jade Biosciences Inc JBIO
Common Stock
2025-10-06 Grant 1,333,126 $9.14 12,184,772
Cogent Biosciences Inc COGT
Common Stock
2025-07-10 Buy 2,777,777 $9.00 24,999,993
Crescent Biopharma Inc CBIO
Stock Option (Right to Buy) · derivative
2025-06-23 Grant 9,023 $0.00
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
2025-06-17 Grant 14,461 $0.00
Apogee Therapeutics Inc APGE
Stock Option (Right to Buy) · derivative
2025-06-17 Grant 14,461 $0.00
showing 20 of 110 most recent transactions
Comparable Firms State AUM
PennantPark Investment Advisers LLC
FL 6,155.9 M
Polen Capital Credit LLC
MA 6,129.5 M
JC Flowers & Co LLC
NY 6,010.1 M
HG VORA Capital Management LLC
NY 5,872.6 M
Torchlight Investors LLC
NY 5,843.9 M
Sun Capital Advisors LP
FL 5,843.3 M
Axium Infrastructure US Inc
NY 5,830.4 M
Saluda Grade Asset Management LLC
NY 5,826.7 M
Dynamic Beta Investments LLC
CT 5,674.3 M
Lime Rock Management LP
CT 5,478.5 M
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com